Skip to main content
SpringerLink
Log in

Epitheliales Ovarialkarzinom

  • Chapter
Management des Ovarialkarzinoms

Part of the book series: Onkologie aktuell ((ONKAKTUELL))

  • 1353 Accesses

Auszug

Das epitheliale Ovarialkarzinom ist gekennzeichnet durch die intraperitoneale Tumorausbreitung im gesamten Abdomen vom kleinen Becken bis zum Zwerchfell. Die lymphogene Dissemination erfolgt entlang dem ovariellen Gefäßbündel in die paraaortalen und über die Parametrien in die pelvinen Lymphknotenstationen (Abb. 14.2a). Bei 10% der Ovarialkarzinome findet sich eine erhebliche Peritonealkarzinose bei nur gering oder gar nicht betrofenen Ovarien. Klinisch und prognostisch entsprechen sie Ovarialkarzinomen im Stadium FIGO III. Für sie gelten die gleichen Therapiekriterien wie für das sekundär peritoneal metastasierte Ovarialkarzinom.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Aletti GD, Dowdy Sc, Podratz KC, Cliby WA (2006) Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100(2):283–7

    Article  PubMed  Google Scholar 

  • Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (2004) Krebs in Deutschland—Häufigkeiten und Trends. 4. Ausgabe, Saarbrücken

    Google Scholar 

  • Arbeitsgemeinschaft Gynäkologische Endoskopie (AGE), Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (1998) Leitlinie zur laparoskopischen Operation von Ovarialtumoren. Frauenarzt 39:1055–1056

    Google Scholar 

  • Benedetti-Panici PB, Maggioni A, Hacker N et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97:560–6

    Article  Google Scholar 

  • Bois A du, Lück HJ, Meier W et al. (2003) A randomized clinical trial of Cisplatin/Paditaxel versus Carboplatin/Paditaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst 95:1320–29

    PubMed  Google Scholar 

  • Bois A du, Rochon J, Lamparter C, Pfisterer für die AGO Organkommission Ovar (2005). Ovarialkarzinom—Versorgungsstruktur und-qualität in Deutschland 2001–2004. Der Frauenarzt 46:560–567

    Google Scholar 

  • Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72:278–87

    Article  PubMed  CAS  Google Scholar 

  • Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–59

    Article  PubMed  Google Scholar 

  • Colombo N, Parma G, Lapresa MT, Maggi F, Piantanda P, Maggioni A (2005) Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer 15(Suppl 3):206–211

    Article  PubMed  Google Scholar 

  • Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23(34):8802–8811

    Article  PubMed  Google Scholar 

  • Earle CC, Schrag D, Neville BA et al. (2006) Effect of surgeon specialty on process of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98(3):151–4

    Article  Google Scholar 

  • Eisenkop SM, Spirtos NM (2001) Procedures required to accomplish complete cytoreductin of ovarian cancer. Is there a correlation with »biological aggressiveness« and survival? Gynecol Oncol 82(3):435–441

    Article  PubMed  CAS  Google Scholar 

  • Elit L, Bondy SJ, Paszat L, Przybysz R, Levine M (2002) Outcomes in surgery for ovarian cancer. Gynecol Oncol 87:260–7

    Article  PubMed  CAS  Google Scholar 

  • Engelen MJA, Kos HE, Willemse PHB et al. (2006) Surgery by consultant oncologist improves survival in patients with ovarian carcinoma Cancer 106:589–98

    Article  PubMed  Google Scholar 

  • Griffiths CT, Parker LM, Lee S, Finkler NJ (2002) The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term-results. Int J Gynecol Cancer 12:323–331

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M, Costa SD, Scharl A (2006) Die Gynäkologie, 2. Aufl, Springer, Heidelberg

    Google Scholar 

  • Kuhn W, Florack G, Roder J et al. (1998) The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer 8:56–63

    Google Scholar 

  • Lecuru F, Desfeux P, Camatte S, Bissery A, Robin F, Blanc B, Querleu D (2004) Stage I ovarian cancer: comparison of laparoscopy and laparotomy on staging and survival. Eur J Gynaecol Oncol 25:571–6

    PubMed  CAS  Google Scholar 

  • Negishi H, Takeda M, Fujimoto T et al. (2004) Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol 94:161–6

    Article  PubMed  Google Scholar 

  • Schmalfeldt B, Bois A du, Burges A et al. (2006) Diagnosis and treatment of malignant ovarian tumors 2005: Rrecommendations of the Kommission Ovar of the AGO. Zentralbl Gynakol 128(1):11–17

    Article  PubMed  CAS  Google Scholar 

  • Tentes A-AK, Mirelis CG, Markakidis SK et al. (2006). Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures. Int J Gynecol Cancer 16: 490–495

    Article  PubMed  Google Scholar 

  • Trimbos JB, Vergote I, Bolis G et al. (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer — Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 95:113–125

    Article  PubMed  CAS  Google Scholar 

  • Vergote I, De Brabanter J, Fyles A et al. (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelail ovarian carcinoma. Lancet 357:176–82

    Article  PubMed  CAS  Google Scholar 

  • Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C (1997) Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 104:1030–5

    PubMed  CAS  Google Scholar 

Literatur

  • Berman ML (2003) Future directions in the surgical management of ovarian cancer. Gynecol Oncol 90: S33–9

    Article  PubMed  Google Scholar 

  • Brand E, Pearlman N (1990) Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 39(2): 115–8

    Article  PubMed  CAS  Google Scholar 

  • Bristow RE, Montz FJ (2001) Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 83(1): 39–48

    Article  PubMed  CAS  Google Scholar 

  • Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5): 1248–59

    Article  PubMed  Google Scholar 

  • Burg ME van der, Vergote I (2003) The role of interval debulking surgery in ovarian cancer. Curr Oncol Rep 5(6): 473–81

    Article  PubMed  Google Scholar 

  • Cacciari N, Zamagni C, Strocchi E et al. (1999) Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look. Eur J Gynaecol Oncol 20(1): 56–60

    PubMed  CAS  Google Scholar 

  • Chi DS, McCaughty K, Diaz JP et al. (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9): 1933–9

    Article  PubMed  Google Scholar 

  • Clough KB, Ladonne JM, Nos C et al. (1999) Second look for ovarian cancer: laparoscopy or Laparotomy? A prospective comparative study. Gynecol Oncol 72(3): 411–7

    Article  PubMed  CAS  Google Scholar 

  • Dam PA van, Tjalma W, Weyler J et al. (1996) Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. Am J Obstet Gynecol 174(3): 943–50

    Article  PubMed  Google Scholar 

  • Eisenkop SM, Friedman RL, Wang HJ (1995) Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76(9): 1606–14

    Article  PubMed  CAS  Google Scholar 

  • Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88(1): 144–53

    Article  PubMed  CAS  Google Scholar 

  • Harter P, Bois A du, Hahmann M et al. (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12): 1702–10

    Article  PubMed  Google Scholar 

  • Hernando JJ, Part TW, Kubler K et al. (2002) Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51(1): 45–52

    Article  PubMed  CAS  Google Scholar 

  • Husain A, Chi DS, Prasad M et al. (2001) The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol 80(1): 44–7

    Article  PubMed  CAS  Google Scholar 

  • Janicke F, Holscher M, Kuhn W et al. (1992) Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70(8): 2129–36

    Article  PubMed  CAS  Google Scholar 

  • Kindermann G, Maassen V, Kuhn W (1995) Laparoscopic preliminary surgery of ovarian malignancies. Experiences from 127 German gynecologic clinics. Geburtshilfe Frauenheilkd 55(12): 687–94

    Article  PubMed  CAS  Google Scholar 

  • Kuhn W, Schmalfeldt B, Pache L et al. (1998) Disease-adapted relapse therapy for ovarian cancer: results of a prospective study. Int J Oncol 13(1): 57–63

    PubMed  CAS  Google Scholar 

  • Kuhn WC (2003) Therapy for recurrent ovarian cancer. Curr Womens Health Rep 3(1): 33–8

    PubMed  Google Scholar 

  • Luesley D, Lawton F, Blackledge G et al. (1988) Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 2(8611): 599–603

    Article  PubMed  CAS  Google Scholar 

  • Malhotra V, Malik R, Gondal R et al. (1986) Evaluation of histological appearance of tissues removed by cavitron ultrasonic surgical aspirator (CUSA). Acta Neurochir (Wien) 81(3–4): 132–4

    Article  CAS  Google Scholar 

  • Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5(1): 26–35

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Rothman R, Hakes T et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9(3): 389–93

    PubMed  CAS  Google Scholar 

  • Meier W, Kimmig R, Lichtenegger W (2001) Die operative Therapie des Rezidivs. Gynäkologe: 1024–1028

    Google Scholar 

  • Munkarah A, Levenback C, Wolf JK et al. (2001) Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 81(2): 237–41

    Article  PubMed  CAS  Google Scholar 

  • Nicoletto MO, Tumolo S, Talamini R et al. (1997) Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission — a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol 15(3): 994–9

    PubMed  CAS  Google Scholar 

  • Oosterhuis JW, Lung PF, Verschueren RC et al. (1985) Viability of tumor cells in the irrigation fluid of the Cavitron Ultrasonic Surgical Aspirator (CUSA) after tumor fragmentation. Cancer 56(2): 368–70

    Article  PubMed  CAS  Google Scholar 

  • Park TW, Kuhn WC (2004) Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 4(4): 639–47

    Article  PubMed  CAS  Google Scholar 

  • Patsner B, Orr JW Jr, Mann WJ Jr et al. (1990) Does serum Ca-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 38(3): 373–6

    Article  PubMed  CAS  Google Scholar 

  • Podratz KC, Malkasian GD Jr, Wieand HS et al. (1988) Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 29(3): 274–82

    Article  PubMed  CAS  Google Scholar 

  • Pölcher M, Braun M, Kuhn W (2004) Das laparoskopisch anoperierte Ovarialkarzinom. Vorgehen und Prognose. Gynäkol Prax 28: 479–488

    Google Scholar 

  • Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351(24): 2489–97

    Article  PubMed  CAS  Google Scholar 

  • Rubin SC, Hoskins WJ, Hakes TB et al. (1988) Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 159(5): 1094–8

    PubMed  CAS  Google Scholar 

  • Rubin SC, Randall TC, Armstrong KA et al. (1999) Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93(1): 21–4

    Article  PubMed  CAS  Google Scholar 

  • Salani R, Santillan A, Zahurak ML et al. (2007) Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 (4): 685–91

    Article  PubMed  Google Scholar 

  • Segna RA, Dottino PR, Mandeli JP et al. (1993) Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11(3): 434–9

    PubMed  CAS  Google Scholar 

  • Trinh H, Ott C, Fanning J (2004) Feasibility of laparoscopic debulking with electrosurgical loop excision procedure and argon beam coagulator at recurrence in patients with previous laparotomy debulking. Am J Obstet Gynecol 190(5): 1394–7

    Article  PubMed  Google Scholar 

  • Tuxen MK, Strauss G, Lund B et al. (1997) The role of second-look laparotomy in the long-term survival in ovarian cancer. Ann Oncol 8(7): 643–8

    Article  PubMed  CAS  Google Scholar 

  • Vaidya AP, Curtin JP (2003) The follow-up of ovarian cancer. Semin Oncol 30(3): 401–12

    Article  PubMed  Google Scholar 

Literatur

  • Alberts DS, Green S, Hannigan EV et al. (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III study randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706–717

    PubMed  CAS  Google Scholar 

  • Alberts DS, Liu PY, Hannigan EV et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955

    Article  PubMed  CAS  Google Scholar 

  • Armstrong DK, Bundy BN, Baergen R et al. (2002) Randomized phase III study of intravenous (iv) paclitaxel and cisplatin versus iv paclitaxel, intraperitoneal (ip) cisplatin and ip paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol 21: 201a (Abstr 803)

    Google Scholar 

  • Bokkel Huinink WW ten, van der Burg MEL, van Oosterom AT et al. (1988) Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev 15 (Suppl B): 9–13

    Article  PubMed  Google Scholar 

  • Bookmann MA, McGuire IIIWP, Kilpatrick D et al. (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14: 1895–1902

    Google Scholar 

  • Burg MEL van der, Lent M van, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–634

    Article  PubMed  Google Scholar 

  • Burger RA, Sill MW, Monk BJ et al. (2005) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 23: Abstract 5009

    Google Scholar 

  • Cannistra SA, Matulonis U, Penson R et al. (2006) Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol 24 (Suppl), 2006 ASCO Annual Meeting Proceedings Part I: Abstract 5006

    Google Scholar 

  • Colombo N, Guthrie D et al. (2003) International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95: 125–132

    Article  PubMed  Google Scholar 

  • Conte PF, Bruzzone M, Carnino F et al. (1991) Carboplatin, Doxorubicin and Cyclophosphamide versus cisplatin, doxorubicin, and cyclophophsphamide: a randomized trial in stage III–IV epithelial ovarian carcinoma. J Clin Oncol 9: 658–663

    PubMed  CAS  Google Scholar 

  • du Bois A, Vach W, Thomssen C, Karck U, Madjar H, Meerpohl HG (1994) Comparison of the emetogenic potential between cisplatin and carboplatin. Acta Oncol 33: 531–535

    Article  PubMed  Google Scholar 

  • du Bois A, Lück HJ, Bauknecht T et al. (1997a) Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 8: 355–361

    Article  PubMed  Google Scholar 

  • du Bois A, Lück HJ, Buser K et al. (1997b) Extended phase II study of paclitaxel as 3 hour infusion in patients with ovarian cancer previouslytreated with platinum. Eur J Cancer 33: 379–384

    Article  PubMed  Google Scholar 

  • du Bois A, Lück HJ, T Bauknecht et al. (1999a) First-line chemotherapy with epirubicin, paclitaxel, and carboplatin (ET-CARBO) for advanced ovarian cancer. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. J Clin Oncol 17: 46–51

    PubMed  Google Scholar 

  • du Bois A, Lück HJ, Meier W et al. for the AGO Ovarian Cancer Study Group (1999b) Cisplatin/ paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial. Proc Am Soc Clin Oncol 18: 356a (Abstr 1374)

    Google Scholar 

  • du Bois A, Weber B, Pfisterer J et al. (2001) Epirubicin/Paclitaxel/Carboplatin (TEC) vs Paclitaxel/Carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Interim results of an AGOGINECO intergroup phase III trial. Proc Am Soc Clin Oncol 20: 202a (Abstr 805)

    Google Scholar 

  • Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654–2666

    PubMed  CAS  Google Scholar 

  • Elit L, Fyles A, Chambers A, Fung Kee Fung M, Convens A and members of the Gynecology Cancer Disease site Group (2004) Adjuvant care for stage I ovarian cancer; Practice guideline report 2004; # 4-13. Verfügbar unter www.cancercare.on.ca/pdf/pebc4-13f.pdf [5.9.2008]

    Google Scholar 

  • Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID) in Zusammenarbeit mit dem Robert-Koch-Institut (RKI) (2006) Krebs in Deutschland — Häufigkeiten und Trends, 5. überarb., aktual. Ausg. Verfügbar unter http://www.rki.de [5.9.2008]

    Google Scholar 

  • Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15: 785–792

    Article  PubMed  CAS  Google Scholar 

  • Gurney H, Crowther D, Anderson H et al. (1990) Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Annal Oncol 1: 427–433

    CAS  Google Scholar 

  • Heintz APM, Odicino F, Maissoneuwe P et al. (2003) Carcinoma of the ovary. In: 25th Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 83 (Suppl 1): 135–66

    Google Scholar 

  • International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cance: the ICON3 randomised trial. Lancet 360: 505–515

    Article  Google Scholar 

  • International Collaborative Ovarian Neoplasm (ICON) Collaborators (2003) International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with earlystage ovarian cancer. J Natl Cancer Inst 95: 125–132

    Article  Google Scholar 

  • Kristensen G, Vergote, I, Stuart G et al. (2002) First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynecological Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol 21: 202a (Abstr 805)

    Google Scholar 

  • Ledermann JA, Frickhofen N, Wandt H, Bengala C, Champion K, Hinke A, Möbus V. on behalf of the EBMT and AGO/AIO (2005) A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support of standard dose chemotherapy (SDC) for first-line treatment of ovarian cancer. J Clin Oncol 23 (Suppl June 1, 2005 ASCO Annual Meeting Proceedings, Part I): abstract 5006

    Google Scholar 

  • Markman M, Bundy BN, Alberts DS et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately highdose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–1007

    PubMed  CAS  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  • Meerpohl HG, Sauerbrei W, Kühnle H, Schumacher M, Pfleiderer A (1997) Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. Gynecol Oncol 66: 75–84

    Article  PubMed  CAS  Google Scholar 

  • Muggia FM, Braly PS, Brady MF et al. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18: 106–115

    PubMed  CAS  Google Scholar 

  • National Cancer Institute: SEER Surveilance, Epidemiology, and End Results (2006) SEER Cancer Statistics Review, 1975–2003. Verfügbar unter http://seer.cancer.gov/csr/1975_2003/ [5.9.2008]

    Google Scholar 

  • Neijt JP, Engelholm SA, Tuxen MK, et al. (2000) Exploratory phasee III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084–3092

    PubMed  CAS  Google Scholar 

  • Omura G, Blessing JA, Ehrlich CE et al. (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 57: 1725–1730

    CAS  Google Scholar 

  • Ozols RF, Bundy BN, Fowler D et al. (1999) Randomized phase III study of cisplatin (CIS)/ paclitaxel (PAC) versus carboplatin (CARBO)/ PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 18: 356a (Abstr 1373)

    Google Scholar 

  • Piccart MJ, Bertelsen K, James K et al. (2000) Randomized Intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophosphamid in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699–708

    Article  PubMed  CAS  Google Scholar 

  • Redman CWE, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GRP (1994) Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Hynaecol 101: 142–146

    CAS  Google Scholar 

  • Robert-Koch-Institut (RKI): Gesundheitsberichterstattung und Epidemiologie: Dachdokumentation Krebs (2006) Interaktive Datenbankabfragen http://www.rki.de

    Google Scholar 

  • Rose PG, Nerenstone S, Brady M et al. (2002) A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 21: 201a (abstr 802)

    Google Scholar 

  • Rozencweig M, Martin A, Beltangady M (1990) Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In: Bunn PA, Canetta R, Ozols RF (eds) Carboplatin (JM-8): Current perspectives and future directions. Saunders, Philadelphia, PA, pp 175–186

    Google Scholar 

  • Rustin GJ, Quinn M, Thigpen T et al. (2004) New Guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96: 487–8

    PubMed  Google Scholar 

  • Swenerton K, Jeffrey J, Stuart G et al. (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10: 718–726

    PubMed  CAS  Google Scholar 

  • Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C (1994) Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced ovarian cancer. J Clin Oncol 12:2066–2070

    PubMed  CAS  Google Scholar 

  • Thigpen T, Stuart G, Bois A du et al.; Gynecologic Cancer Intergroup; GOG; NCIC-CTG; AGO-OVAR; ANZ-GOG; JGOG; GINECO; SGCTG; MRC/NCRI; NSGO; RTOG; GEICO; EORTC (2005) Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 16 (Suppl 8): viii13–viii19

    Article  PubMed  Google Scholar 

  • Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma (2003) European Organisation for Research and Treatment of Cander — Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 95: 113–125

    Google Scholar 

  • Trope C, Kaern J, Hogberg T et al. (2000) Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 11: 281–8

    Article  PubMed  CAS  Google Scholar 

  • Tumorregister München (TRM) (2006). http://www.tumorregister-muenchen.de

    Google Scholar 

  • Vesey PA (2002) Survival and longterm toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 21: 202a (Abstr 804)

    Google Scholar 

  • Wagner U, Kohler S, Reimartz S et al. (2001) Immunological consolidation of ovarian carcinoma recurrens with monoclonal antiidiotype antibody ACA 125. Clin Cancer Res 7: 1154–1162

    PubMed  CAS  Google Scholar 

Literatur

  • Aghajanian C, Gogas H, Fennelly D et al. (1996) Second-line paclitaxel therapy in patients with ovarian cancer previously treated with a taxane. Proc Am Soc Clin Oncol 15: 69

    Google Scholar 

  • Bajetta E, Di Leo A, Biganzoli L et al. (1996) Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 14: 2546–2551

    PubMed  CAS  Google Scholar 

  • Bois A du, Lück HJ, Bauknecht T, Pfisterer J, Meier W (2000) 2nd-line Chemotherapie nach Platin-oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998. Geb Frau 60: 41–58

    Article  Google Scholar 

  • Bolis G, Villa A, Guanerio P et al. (1996) Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer 77: 123–131

    Article  Google Scholar 

  • Bookman MA, Malmström H, Bolis G et al. (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345–3352

    PubMed  CAS  Google Scholar 

  • Bristow RE (2000) Surgical standards in the management of ovarian cancer. Curr Opin Oncol 12: 474–480

    Article  PubMed  CAS  Google Scholar 

  • Burger RA, Burman S, White R, DiSaia PJ (1996) Phase II trial of navelbine in advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 15: 286

    Google Scholar 

  • Burnett AF, Barter JF, Potkul RK, Barnes WA (1994) Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer. Am J Clin Oncol 17: 490–493

    Article  PubMed  CAS  Google Scholar 

  • Chen LM, Karlan BY (2000) Recurrent ovarian carcinoma: is there a place for surgery? Semin Surg Oncol 19: 62–68

    Article  PubMed  CAS  Google Scholar 

  • Clarke-Pearson DL, Van Le L, Ivason T et al. (1998) A phase II study of oral topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 17: 363A

    Google Scholar 

  • Colombo N, Speyer JL, Green M et al. (1989) Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol 23: 323–328

    Article  PubMed  CAS  Google Scholar 

  • Creemers GJ, Bolis G, Gore M et al. (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14: 3056–3061

    PubMed  CAS  Google Scholar 

  • Donovan JT, Veronikis DK, Powell JL, Lundy LE, Prefontaine M (1994) Cytoreductive surgery for ovarian cancer with the cavitron ultrasonic surgical aspirator and the development of disseminated intravascular coagulation. Obstet Gynecol 83: 1011–1014

    Article  PubMed  CAS  Google Scholar 

  • Dunton CJ, Neufeld J, Carlson JA et al. (1998) Secondary response of ovarian tumors to topotecan treatment. Gynecol Oncol 69: 258–259

    Article  PubMed  CAS  Google Scholar 

  • Eisenhauer EA, Vermorken JB, Glabbeke M van (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8: 963–968

    Article  PubMed  CAS  Google Scholar 

  • Eisenkop SM, Friedman RL, Wang H (1995) Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer 76: 1606–1614

    Article  PubMed  CAS  Google Scholar 

  • Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88: 144–153

    Article  PubMed  CAS  Google Scholar 

  • Ezcurdia L, Jovtis SL, Mickiwicz E et al. (1997) Paclitaxel in platinum-resistant ovarian cancer patients. Sem Oncol 24 (Suppl 15): S15–53, S15–56

    CAS  Google Scholar 

  • Francis P, Schneider J, Hann L et al. (1994) Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12: 2301–2308

    PubMed  CAS  Google Scholar 

  • Friedlander M, De Gramont A, Millward MJ et al. (1997) Activity of gemictabine in stage 3 or 4 ovarian cancer: patients previously treated with cisplatin (CP)-containing regimens. Eur J Cancer 33: S121–S122

    Google Scholar 

  • Gemignani ML, Chi DS, Gurin CC, Curtin JP, Barakat RR (1999) Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol 72: 407–410

    Article  PubMed  CAS  Google Scholar 

  • Goldberg JM, Piver MS, Hempling RH, Recio FO (1996) Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 63: 312–317

    Article  PubMed  CAS  Google Scholar 

  • Gordon A, Bookman M, Malmstrom H et al. (1996) Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paditaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15: 282

    Google Scholar 

  • Gordon AN, Hainsworth J, Moore M et al. (1998a) Doxil (doxorubicin HCL liposomal injection) in the treatment of patients with refractory advanced ovarian carcinoma — results of an interim analysis. Proc Am Soc Clin Oncol 17: 1345

    Google Scholar 

  • Gordon A, Carmichael J, Malfetano J et al. (1998b) Final analysis of a phase III randomized study of Topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma (OC): International Topotecan Study Group. Proc Am Soc Clin Oncol 17: 1374

    Google Scholar 

  • Gropp M, Meier W, Hepp H (1998) Treosulfan as an effective secondline therapy in ovarian cancer. Gynecol Oncol 71: 94–98

    Article  PubMed  CAS  Google Scholar 

  • Guastalla JP, Pujade-Lauraine E, Weber B et al. (1998) Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. Ann Oncol 9: 37–43

    Article  PubMed  CAS  Google Scholar 

  • Gwyther SJ, Gore ME, Bokkel Hiunink W ten et al. (1997) Results of independent radiological review of over 400 patients with advanced ovarian cancer treated with topotecan (Hycamtin). Proc Am Soc Clin Oncol 16: 1255

    Google Scholar 

  • Harter P et al. (2006) Surgery in recurrent ovarian cancer — The Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Desktop Ovar Trial. Ann of Surg Oncol (in press)

    Google Scholar 

  • Havsteen H, Bertelsen K, Gadeberg CC et al. (1996) A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer. Gynecol Oncol 63: 210–215

    Article  PubMed  CAS  Google Scholar 

  • ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGOOVAR-2.2 trial. Lancet 361: 2099–2106

    Article  CAS  Google Scholar 

  • Jänicke F, Hölscher M, Kuhn W et al. (1992) Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129–2136

    Article  PubMed  Google Scholar 

  • Johnston CM, Pearl ML, Reynolds RK, Roberts JA, Morley GW (1995) Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel. Eur J Gynaec Oncol 16: 439–447

    CAS  Google Scholar 

  • Kavanagh JJ, Tresukosol D, Edwards C et al. (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13: 1584–1588

    PubMed  CAS  Google Scholar 

  • Kavanagh JJ, Kudelka AP, Gonzales de Leon C et al. (1996) Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2: 837–842

    PubMed  CAS  Google Scholar 

  • Knapp RC (1994) Reflections on ovarian cancer: A 33-year experience. Gynecol Oncol 54: 124–129

    Article  PubMed  CAS  Google Scholar 

  • Kurtz JE, Deplanque G, Duclos B et al. (1998) Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study. Gynecol Oncol 70: 414–417

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Hoskins W (1992) Responses to salvage therapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10: 513–514

    PubMed  CAS  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  • Meier W, du Bois A (1998) Palliative therapeutische Möglichkeiten beim Ovarialkarzinom. Onkologe 4: 1153–1158

    Article  Google Scholar 

  • Meier W, Kimmig R, Lichtenegger W (2001) Die operative Therapie des Rezidivs. Gynäkologe 34: 1024–1028

    Article  Google Scholar 

  • Mendiola C, Garcia-Ribas I, Cubedo R et al. (1995) High response rate of taxol in platinum pretreated advanced ovarian cancer. Proc Am Soc Clin Oncol 14: 278

    Google Scholar 

  • Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edward CI, Springer CA (1989) Secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol 34: 334–338

    Article  PubMed  CAS  Google Scholar 

  • Muggia FM, Hainsworth JD, Jeffers S et al. (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987–993

    PubMed  CAS  Google Scholar 

  • Munkarah A, Levenback C, Wolf JK et al. (2001) Secondary cytoreductive surgery for localized intra-abdominal recurrence in epithelial ovarian cancer. Gynecol Oncol 81: 237–241

    Article  PubMed  CAS  Google Scholar 

  • Neijt JP, Kaufmann M, Bauknecht T et al. (1996) Gemcitabine in pretreated ovarian cancer. Ann Oncol 7: 70

    Google Scholar 

  • Pectasides D, Papadopulou M, Varthalitis J et al. (1998) Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Oncology 55: 228–234

    Article  PubMed  CAS  Google Scholar 

  • Pfisterer J, Ledermann JA (2006) Management of platinum sensitive recurrent ovarian cancer. Semin Oncol April 33/2 (Suppl 6): 12–6

    Article  CAS  Google Scholar 

  • Pfisterer J, Hilpert F, Bois A du, Meier W (2001) Second-line Therapie des Ovarialkarzinoms. Aktuelle Standards und neue Ansätze. Med Welt 52: 133–136

    Google Scholar 

  • Pfisterer J, Harter P, Canzler U et al. the AGO Ovarian Committee (2005) The role of su8rgery in recurrent ovarian cancer. Int J Gynecol Cancer Nov–Dec; 15 (Suppl 3): 195–8

    Article  Google Scholar 

  • Rose PG (2000) Surgery for recurrent ovarian cancer. Semin Oncol 27 (Suppl): 17–23

    PubMed  CAS  Google Scholar 

  • Rose PG Fusco N, Fluellen L, Rodriguez M (1998) Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 16: 1494–1497

    PubMed  CAS  Google Scholar 

  • Safra T, Jeffers S, Groshen S et al. (1997) Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): results from three consecutive phase I/II studies. Proc Am Soc Clin Oncol 16: 349A

    Google Scholar 

  • Shapiro JD, Millward MJ, Rischin D et al. (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89–93

    Article  PubMed  CAS  Google Scholar 

  • Stuart G, Bertelsen K, Mangioni C et al. (1998) Updated analysis shows highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NICIC-CTG and Scottish intergroup trial. Proc Am Soc Clin Oncol 17: 1394

    Google Scholar 

  • Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ (1997) Topotecan in platinum-and paclitaxel-resitant ovarian cancer. Gynecol Oncol 66: 349

    Article  Google Scholar 

  • Tresukol D, Kudelka AP, Gonzales de Leon C et al. (1996) Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaecol Oncol 17: 188–191

    Google Scholar 

  • Trope C, Kaern J, Hogberg T (1998) A phase II study of paclitaxel and doxorubicin as second-line treatment in recurrent ovarian cancer after cisplatin failure. Gynecol Oncol 68: 123

    Google Scholar 

  • Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, Hoskins WJ (1995) Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 57: 61–65

    Article  PubMed  CAS  Google Scholar 

  • Wagner U Blohmer JU, Lück HJ (2001) Medikamentöse Rezidivtherapie. Gynäkologe 34: 1020–1023

    Article  Google Scholar 

  • Williams CI (1998) Tamoxifen in relapsed ovarian cancer: A systematic review. Int J Gynecol Cancer 8: 89–94

    Article  Google Scholar 

  • Zang RY, Zhang ZY, Li ZT, Cai SM, Tang MO, Chen J, Liu Q (2000) Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol 26: 798–804

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Baker VV. Salvage therapy for recurrent epithelial ovarian cancer. Hematol Oncol Clin North Am 2003;17:977–988

    Article  PubMed  Google Scholar 

  • Boye E, Lindegaard MW, Paus E, Skretting A, Davy M, Jakobsen E. Whole-body distribution of radioactivity after intraperitoneal administration of 32P colloids. Br J Radiol 1984;57:395–402

    Article  PubMed  CAS  Google Scholar 

  • Britten RA, Peacock J, Warenius HM. Collateral resistance to photon and neutron irradiation is associated with acquired cis-platinum resistance in human ovarian tumour cells. Radiother Oncol 1992;23:170–175

    Article  PubMed  CAS  Google Scholar 

  • Cardenes H, Randall ME. Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions. Semin Radiat Oncol 2000a;10:61–70

    Article  PubMed  CAS  Google Scholar 

  • Cardenes H, Randall ME. Radiotherapy in epithelial ovarian cancer: state of the art. Forum (Genova) 2000b;10:335–352

    CAS  Google Scholar 

  • Cmelak AJ, Kapp DS. Long-term survival with whole abdominopelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer. Gynecol Oncol 1997;65:453–460

    Article  PubMed  CAS  Google Scholar 

  • Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience. Cancer 1985;55:2285–2290

    Article  PubMed  CAS  Google Scholar 

  • Einhorn N, Trope C. Ridderheim M, Boman K, Sorbe B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol 2003;42:562–566

    Article  PubMed  Google Scholar 

  • Fyles AW, Dembo AJ, Bush RS et al. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys 1992;22:847–851

    PubMed  CAS  Google Scholar 

  • Gelblum D, Mychalczak B, Almadrones L, Spriggs D, Barakat R. Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma. Gynecol Oncol 1998;69:36–41

    Article  PubMed  CAS  Google Scholar 

  • Greiner RH. Radiotherapeutische Möglichkeiten beim Ovarialkarzinom. Onkologe 1998;4:1147–1152

    Article  Google Scholar 

  • Hogberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40:340–360

    Article  PubMed  CAS  Google Scholar 

  • Lund B, Williamson P. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol 1990;76:617–622

    PubMed  CAS  Google Scholar 

  • MacGibbon A, Bucci J, MacLeod C, Solomon J, Dalrymple C, Firth I, Carter J. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecol Oncol 1999;75:62–67

    Article  PubMed  CAS  Google Scholar 

  • National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55:S4–14

    Article  Google Scholar 

  • Ostapovicz, DM, Keit J, Brady LW. Ovary. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology. 3rd Ed. Philadelphia (NY): Lippincott-Raven, 1998:1853–1879

    Google Scholar 

  • Pickel H, Lahousen M, Petru E, Stettner H, Hackl A, Kapp K, Winter R. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol 1999;72:215–219

    Article  PubMed  CAS  Google Scholar 

  • Reddy S, Lee MS, Yordan E, Graham J, Sarin P, Hendrickson FR. Salvage whole abdomen radiation therapy: its role in ovarian cancer. Int J Radiat Oncol Biol Phys 1993;27:879–884

    PubMed  CAS  Google Scholar 

  • Siler DF, Wheeless CR Jr, Dubin NH. Radiotherapy as a cisplatin-sensitizer in a resistant ovarian carcinoma cell line. Cancer 1996;77:1850–1853

    Article  PubMed  CAS  Google Scholar 

  • Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 2003;13:278–286

    Article  PubMed  CAS  Google Scholar 

  • Takai N, Utsunomiya H, Kawano Y, Nasu K, Narahara H, Miyakawa I. Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma. Arch Gynecol Obstet 2002;267:98–100

    Article  PubMed  CAS  Google Scholar 

  • Tinger A, Waldron T, Peluso N et al. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys 2001;51:1256–1263

    PubMed  CAS  Google Scholar 

  • Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021–1027

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Balbi G, Piano LD, Cardone A, Cirelli G (2004) Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 14:799–803

    Article  PubMed  CAS  Google Scholar 

  • Bois A du, Meier W, Lück HJ, Emons G et al. (2002) Chemotherapy versus hormonal treatment in platinum-and paditaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Annals of Oncology 13:251–257

    Article  Google Scholar 

  • Duffaud F, Burg ME van der, Namer M, Vergote I et al. (2001) D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study. Anti-Cancer Drugs 12:159–162

    Article  PubMed  CAS  Google Scholar 

  • Emons G, Kavanagh JJ (1999) Hormonal interactions in ovarian cancer. Hematology/Oncology Clinics of North America 13:124–161

    Article  Google Scholar 

  • Emons G, Schulz KD (1996) Growth regulation of epithelial ovarian cancer by hormones, peptide growth factors and cytokines. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone-dependend cancer. Dekker, New York, pp 509–539

    Google Scholar 

  • Emons G, Schulz KD (2000) Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent Results Cancer Res 153:83–94

    PubMed  CAS  Google Scholar 

  • Emons G, Ortmann O, Teichert HM, Fassl H et al. (1996) Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: a prospective double-blind randomized trial. Cancer 78:1452–1460

    Article  PubMed  CAS  Google Scholar 

  • Emons G, Gründker C, Günthert AR, Westphalen S, Kavanagh J, Verschraegen C (2003) GnRH antagonists in the treatment of gynecological and breast cancers. Endocrine-Related Cancer 10:291–299

    Article  PubMed  CAS  Google Scholar 

  • Ho SM (2003) Estrogen, progesterone and epithelial ovarian cancer. Reproductive Biology and Endocrinology 1:73. Verfügbar unter www.rbej.com/content/pdf/1477-7827-1-73.pdf[11.9.2008]

    Article  PubMed  Google Scholar 

  • Lacey JV, Mink PJ, Lubin JH et al. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341

    Article  PubMed  CAS  Google Scholar 

  • Loprinzi CL, Ellison NM, Schaid DJ et al. (1990) Controlled trial of megestol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127–1132

    Article  PubMed  CAS  Google Scholar 

  • Makar AP (2000) Hormone therapy in epithelial ovarian cancer. Endocrine-Related Cancer 7:85–93

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer. Clinical Cancer Research 6:4201–4204

    PubMed  CAS  Google Scholar 

  • Marth C, Sørheim N, Kaern J, Tropé C (1997) Tamoxifen in the treatment of recurrent ovarian carcinoma. Int J Gynecol Cancer 7:256–261

    Article  Google Scholar 

  • Ohtani K, Sakamoto H, Kikuchi A et al. (2001) Follicle-stimulating hormone promotes the growth of human epithelial ovarian cancer cells through the protein kinase C-mediated system. Cancer Letters 166:207–213

    Article  PubMed  CAS  Google Scholar 

  • Paskeviciute L, Roed H, Engelholm SA (2002) No rules without exception: long — term complete remission observed in a study using a LH-RH Agonist in platinum-refractory ovarian cancer. Gynecol Oncol 86:297–301

    Article  PubMed  Google Scholar 

  • Perez-Gracia JL, Carrasco EM (2002) Tamoxifen therapy of ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 84:201–209

    Article  PubMed  CAS  Google Scholar 

  • Pfisterer J, Bois A du (2004) Das rezidivierten Ovarialkarzinom. Neue therapeutische Entwicklungen. Gynäkologe 37:929–935

    Article  Google Scholar 

  • Riman T, Dickman PW, Nilsson S et al. (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94:497–504

    PubMed  CAS  Google Scholar 

  • Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospectiv study of US women. JAMA 285:1460–1465

    Article  PubMed  CAS  Google Scholar 

  • Royar J, Becher H, Chang-Claude J (2001) Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95:370–374

    Article  PubMed  CAS  Google Scholar 

  • Verschraegen CF, Westphalen S, Hu W, Loyer E et al. (2003) Phase II study of Cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 90:552–559

    Article  PubMed  CAS  Google Scholar 

  • Wilailak S, Linasmita V, Srisupundit S (2001) Phase II study of highdose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anti-Cancer Drugs 12:719–724

    Article  PubMed  CAS  Google Scholar 

  • Williams CJ, Simera I. Tamoxifen for relapse of ovarian cancer (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons

    Google Scholar 

  • Zidan J, Zohar S, Mijiritzky I, Kral S, Bilenca B (2002) Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. Isr Med Assoc J 4:597–599

    PubMed  CAS  Google Scholar 

Literatur

  • Balkwill F, Schlom J, Berek J, Epenetos A, Bookman M, Freedman R, Wilbanks G (2003) Discussion: Immunological therapeutics for ovarian cancer. Gynecol Oncol 88:110–113

    Article  Google Scholar 

  • Berek JS, Taylor PT, Gordon A et al. (2004) Randomized, placebocontrolled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507–3516

    Article  PubMed  CAS  Google Scholar 

  • Burger RA, Sill M, Monk BJ, Greer B, Sorosky J (2005) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 23, 5009

    Google Scholar 

  • Curiel TJ, Coukos G, Zou L et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949

    Article  PubMed  CAS  Google Scholar 

  • Disis ML, Gooley TA, Rinn K et al. (2002) Generation of T-cell immunity to the HER2/neu protein after active immunization with HER2/neu peptide-based vaccines. J Clin Oncol 20:2624–2632

    Article  PubMed  CAS  Google Scholar 

  • Jäger M, Ströhlein A, Schoberth A, Burges A, Heiss MM, Lindhofer H (2004) Immunotherapy with the trifuncional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study. J Clin Oncol 22:2504–2510

    Article  Google Scholar 

  • Reinartz S, Köhler S, Schlebusch H et al. (2004) Vaccination of patients wioth advanced ovarian carcinoma with the anti-idiotype ACA125: Immunological response and survival (Phase Ib/II). Clin Cancer Res 10:1580–1587

    Article  PubMed  CAS  Google Scholar 

  • Seiden M, Benigno BB (2004) A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). J Clin Oncol 22:5008

    Google Scholar 

  • Zhang L, Conejo-Garcia JR, Katsaros D et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Eng. J. Med. 348:203–213

    Article  CAS  Google Scholar 

Literatur

  • Alvarez RD, Gomez-Navarro J, Wang M et al., Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2, 524–530 (2000).

    Article  PubMed  CAS  Google Scholar 

  • AstraZeneca, Lung cancer trial results show no improvement for the combined treatment of Iressa (ZD 1839) with standard platinum-based chemotherapy [press release]. August 19 (2002).

    Google Scholar 

  • Baselga J, Rischin D, Ranson M et al., Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20, 4292–4303 (2002)

    Article  PubMed  CAS  Google Scholar 

  • Bast RC Jr, Mills GB, Molecular mechanisms of pathogenesis and progression of epithelial ovarian cancer. In: Leung PC, Adashi EY, eds. The Ovary, 2nd ed. Elsevier Science: San Diego, 2003

    Google Scholar 

  • Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr, The p53 tumor suppressor gene frequently is altered in gnecologic cancers. Am J Obstet Gynecol 170, 246–252 (1994)

    PubMed  CAS  Google Scholar 

  • Berek JS, Schultes BS, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21, 168S–174S (2003)

    Article  PubMed  Google Scholar 

  • Berek JS, Taylor PT, Gordon A et al. Randomized, placebo-controlled study of oregomovab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22, 3507–3516 (2004)

    Article  PubMed  CAS  Google Scholar 

  • Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowith IR, Evaluation of monoclonal humanized antiHER2 antibody, trastuzumab, in patients with recurrent of refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21, 283–290 (2003)

    Article  PubMed  CAS  Google Scholar 

  • Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Onc 23, 5009 (2005)

    Google Scholar 

  • Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistent ovarian cancer. Proc Am Soc Clin Onc 24, 5006 (2006)

    Google Scholar 

  • Carmeliet P, Angiogenesis in life, disease and medicine. Nature 438, 932–6 (2005)

    Article  PubMed  CAS  Google Scholar 

  • Chan WY, Cheung KK, Schorge JO et al., BCL-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156, 409–417 (2000)

    PubMed  CAS  Google Scholar 

  • Ciardiello F. Epidermal growth factor tyrosine kinase inhibitors as anti-cancer agents. Drugs 60 Suppl 1, 25–32 (2000)

    Article  PubMed  CAS  Google Scholar 

  • Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2(4), 246–51, review (2003)

    Article  PubMed  CAS  Google Scholar 

  • Deshane J, Cabrera G, Grim JE et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB2 single-chain antibody. Gynecol Oncol 59, 8 (abstract) (1995)

    Article  PubMed  CAS  Google Scholar 

  • Deveraux OL, Roy N, Stennide HR et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by dirct inhibiton of distinct caspases. EMBO J 17(8), 2215–23 (1998)

    Article  PubMed  CAS  Google Scholar 

  • DiSaia PJ, Bloss JD, Treatment of ovarian cancer: new strategies. Gynecol Oncol 90(2), Suppl 1, S24–S32 (2003)

    Article  PubMed  CAS  Google Scholar 

  • Drevs J, Medinger M, Mross K et al. Phase I clinical evaluation of AZZD 2171, a highly potent VEGF receptor tyrisine kinase inhibitor in patients with advanced tumors. Proc Am Soc Clin Onc 23, # 30002 (2005)

    Google Scholar 

  • Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swerton KD. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15, 1023–34 (2005)

    Article  PubMed  CAS  Google Scholar 

  • Ferrara N, VEGF and the quest for tumour angiogenesis factors. Nature Rev 2, 795–803 (2002)

    Article  CAS  Google Scholar 

  • Finkler N, Gordon A, Crozier M et al., Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoms. In: Program/Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12–15, 2001; San Francisco, CA. Abstract No. 831 (2001)

    Google Scholar 

  • Foe R, Guarini A, Cignetti A, Cronin K, Rosenthal F, Gansbacher B, Cytokine gene therapy: a new strategy for the management of cancer patients. Nat Immun 13, 65–75 (1994)

    Google Scholar 

  • Folkman J, Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182–6 (1971)

    Article  PubMed  CAS  Google Scholar 

  • Folkman J, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27–31 (1995)

    Article  PubMed  CAS  Google Scholar 

  • Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-1: a pilot trial. J Immunother Emphasis Tumor Immunol 16, 198–210 (1994)

    PubMed  CAS  Google Scholar 

  • Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN, The “Bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53, 5274–5283 (1993)

    PubMed  CAS  Google Scholar 

  • Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, Marrogi A, The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum Gene Ther 6, 927–939 (1995)

    Article  PubMed  CAS  Google Scholar 

  • Gomez-Manzano C, Fueyo J, Kyritsis AP et al., Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56, 694–699 (1996)

    PubMed  CAS  Google Scholar 

  • Gordon A, Whiteside T, Nicodemus C, Schultes B, Noujaim A, An interim assessment of OvaRex TM Mab-B43.13 in the management of recurrent ovarian cancer. In: Program/Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12–15, 2001, Abstract No. 2499 (2001)

    Google Scholar 

  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57–70, Review (2000)

    Article  PubMed  CAS  Google Scholar 

  • Havrilesky L, Berchuck A, Hamdan H, Walsh K, Leon J. Relationship between p53 muation, p53 overexpression and survival in advanced ovarian cancers treated on gynecologic oncology group protocols 114 and 132. Proceedings of the Society of Gynecologic Oncology 20th Annual Meeting. Gynecologic Oncology 72, 445 (Abstract 8) (1999)

    Google Scholar 

  • Hayflick L, Mortality and immortality at the cellular level. A review. Biochemistry 62, 1180–1190 (1997)

    PubMed  CAS  Google Scholar 

  • Hofland H, Huang L, Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. Biochem Biophys Res Commun 207, 492–496 (1995)

    Article  PubMed  CAS  Google Scholar 

  • Hortobagyi GN, Ueno NI, Xia W et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19, 3422–3433 (2001)

    PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W et al., Bevacizumab plus irinotecan, fluoro-uracil and leucovorin for metastatic colo-rectal cancer. N Engl J Med 350, 2335–42 (2004)

    Article  PubMed  CAS  Google Scholar 

  • Janicek MF, Sevin BU, Nguyen HN, Averette HE, Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines. Gynecol Oncol 59, 87–92 (1995)

    Article  PubMed  CAS  Google Scholar 

  • Johnstone RW, Ruefli AA, Lowe SW. Aopotosis. A link between cancer genetics and chmeotherapy. Cell 108, 153–164 (2000)

    Article  Google Scholar 

  • Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1(1), 51–64, Review (1994)

    PubMed  CAS  Google Scholar 

  • Jolly D, Viral vector systems for gene therapy. Cancer Gene Ther 1, 51–64 (2000)

    Google Scholar 

  • Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N, p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 14, 165–171 (2001)

    PubMed  CAS  Google Scholar 

  • Li S, Han H, Carcanglu ML et al. Andvanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 51(1), 21–5 (1993)

    Article  PubMed  CAS  Google Scholar 

  • Link CJ Jr, Moorman D, Seregina T, Levy JP Schabold KJ, A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gen Hter 7, 1161–1179 (1996)

    Google Scholar 

  • Liu TJ, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL, Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55, 3117–3122 (1995)

    PubMed  CAS  Google Scholar 

  • Longo R, Samiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G, Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis 5, 237–56 (2002)

    Article  PubMed  CAS  Google Scholar 

  • Marks JR, Davidoff AM, Kerns BJ et al., Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51, 2979–2984 (1991)

    PubMed  CAS  Google Scholar 

  • Masanek U, Stammler G, Volm M, Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol 2, 37–41 (2002)

    Article  PubMed  CAS  Google Scholar 

  • Mercola D, Cohen JS, Antisense approaches to cancer gene therapy. Cancer Gene Ther 2, 47–59 (1995)

    PubMed  CAS  Google Scholar 

  • Meric JB et al., Zd 1839 »Iressa«. Bull Cancer 87(12): 873–6 (2000)

    PubMed  CAS  Google Scholar 

  • Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H, Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93, 1831–1835 (1996)

    Article  PubMed  CAS  Google Scholar 

  • Miyashita T, Krajewski S, Krajewska M et al., Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799–1805 (1994)

    PubMed  CAS  Google Scholar 

  • Mor G, Straszewski S, Kamsteeg M, Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. Biochem Pharmacol 64, 1305–1315 (2002)

    Article  PubMed  CAS  Google Scholar 

  • Muller M, Strand S, Hug H et al., Drug-induced apoptosis in hepatoma cells is mediated by the CD59 (APO-1/Fas) receptor ligand system and involves activation of wild-type p53. J Clin Invest 99, 403–413 (1997)

    Article  PubMed  CAS  Google Scholar 

  • Nasi ML, Castiglione M, Cydooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled? Ann Oncol 13, 1169–1171 (2002)

    Article  PubMed  CAS  Google Scholar 

  • Noujaim AA, Schultes BC, Baum RP, Madiyalakan R, Induction of CA125-specific B and T cell responses in patients injected with Mab-B43.13: evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 16, 187–203 (2001)

    Article  PubMed  CAS  Google Scholar 

  • Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H, BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95, 2302–2306 (1998)

    Article  PubMed  CAS  Google Scholar 

  • Pfisterer J, Bois A du, Sehouli J et al. The anti-idiotypic antibody ab-agovomab in patients with recurrent ovarian cancer — A phase I trial of the AGO-OVAR. Ann Oncol 17(10), 1568–77 (2006)

    Article  PubMed  CAS  Google Scholar 

  • Raymond E, Faivre S, Armand JP, Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60, Suppl 1, 15–23 (2000)

    Article  PubMed  CAS  Google Scholar 

  • Reles A, Wen WH, Schmider A et al., Correlation of p53 muatations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7(10), 2984–2997 (2001)

    PubMed  CAS  Google Scholar 

  • Rosen LS, Clinical experience with angiogensis signaling inhibitors: focus on vascular, endothelial growth factor (VEGF) blockers. Cancer Control 9, Suppl, 36–44 (2002)

    PubMed  Google Scholar 

  • Rosenfeld ME, Feng M, Michael SI, Siegal GP, Alvarez RD, Curiel DT, Adenoviral-mediated delivery of the herpes simplex virus thymidine kinse gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res 1, 1571–1580 (1995)

    PubMed  CAS  Google Scholar 

  • Roses AD. Idiosyncratic reactions to drugs: can medicine response profiles provide a dynamic drug surveillance system? Clin Chem Lab Med 38(9) 815–8 (2000)

    Article  PubMed  CAS  Google Scholar 

  • Rudlowski C, Pickart AK, Fuhlijahn C, Friepörtner T, Schlehe B, Biesterfeld S, Schroeder W, Prognostic significance of vascular-endothelial-growth-factor (VEGF) expression in ovarian cancer patients: a long-term-follow-up. Int J Gynecol Cancer 16, 183–9 (2006)

    Article  PubMed  Google Scholar 

  • Ruf P, Lindhofer H, Induction of a long-lasting anti-tumour immunity by a trifunctional bispecific antibody. Blood 98, 2526–2536 (2001)

    Article  PubMed  CAS  Google Scholar 

  • Runnebaum IB, Kieback DG, Möbus VJ, Tong XW, Kreienberg R, Subcellular localization of accumulated p53 in ovarian cancer cells. Gynecol Oncol 61(2), 266–271 (1996)

    Article  PubMed  CAS  Google Scholar 

  • Santosa JT, Tang DC, Lane SB et al., Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 59, 171–178 (1995)

    Article  Google Scholar 

  • Schröder W, Schwulera U, Lissner R, Bender HG. Animal experiment, pharmacokinetic and clinical studies of intraperitoneal therapy with interleukin-2 (n ll-2) in patients ovarian carcinoma. Gynakol Geburtshilfliche Rundsch 35, Suppl 1, 46–52 (1995)

    Article  PubMed  Google Scholar 

  • Schröder W, Campone M, Abadie S et al., A phase IB, open label, safety and pharmacokinetic (PK) study of escalating does of PTK 787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (pts) with stage IC to IV epithelial ovarian cancer (EOC) Proc Am Soc Clin Onc 24, # 5075 (2006)

    Google Scholar 

  • See HT, Kavanagh JJ, Hu W, Bast RC, Targeted therapy for epithelial ovarian cancer: Current status and future prospects. Int J Cancer 13, 701–734 (2003)

    Article  CAS  Google Scholar 

  • Song K, Li Z, Seth P, Cowan KH, Sinha BK, Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol Res 9, 603–609 (1997)

    PubMed  CAS  Google Scholar 

  • Takhashi T, Ogo M, Hibino T. Proteolytic activation of PKN by caspase-3 or related protease during apoptosis. Proc Natl Acad Sci USA 95(20), 11566–71 (1998)

    Article  Google Scholar 

  • Wagner U, Bois A du, Pfisterer J et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistent to platinum taxane based therapy — a phase II trial of the AGO Ovarian Cancer Study Group (AOG-OVAR 2.6). Gynecol Oncol 105(1), 132–7 (2007)

    Article  PubMed  CAS  Google Scholar 

  • Walker TL, Dass CR, Burton MA, Enhanced in vivo tumour response from combination of carboplatin and low-dose c-myc antisense oligonucleotides. Anticancer Res 22, 2237–2245 (2002)

    PubMed  CAS  Google Scholar 

  • Wood JM, Bold G, Buchdunger E et al., PTK 787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor induced responses and tumor growth after oral administration. Cancer Res 60, 2178–89 (2000)

    PubMed  CAS  Google Scholar 

  • Xerri L, Devilard E, Hassoun J, Mawas C, Birg F, Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 50, 87–91 (1997)

    Article  PubMed  CAS  Google Scholar 

  • Yang C, Cirielli C, Capogrossi MC, Passaniti A, Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55, 4210–4213 (1995)

    PubMed  CAS  Google Scholar 

  • Yu D, Matin A, Xis W, Sorgi F, Huang L, Huang MC, Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 11, 1383–1388 (1995)

    PubMed  CAS  Google Scholar 

  • Yuen AR, Halsey J, Fisher GA et al., Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 5, 3357–3363 (1999)

    PubMed  CAS  Google Scholar 

  • Zhang H, Somasundaram K, Peng Y et al., BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16, 1713–1721 (1998)

    Article  PubMed  CAS  Google Scholar 

  • Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA, High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1, 5–13 (1994)

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frauenklinik der Technischen, Universität München Klinikum rechts der Isar, Ismaninger Str. 22, 81675, München

    Prof. Dr. med. B. Schmalfeldt

  2. Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, D-30625, Hannover

    PD Dr. T. W. Park-Simon

  3. Universitätsfrauenklinik, Med. Einrichtungen der Rheinischen, Friedrich-Wilhelm-Universität, Sig mund-Freud-Straße 25, 53105, Bonn

    Dr. M. Pölcher & Prof. Dr. med. W. Kuhn

  4. Klinik für Gynäkologie und Gyn. Onkologie, Dr.-Horst-Schmidt-Kliniken, Ludwig-Erhard-Straße 100, 65199, Wiesbaden

    Prof. Dr. med. A. du Bois

  5. Universitätsfrauenklinik, Prittwitzstraße 43, 89075, Ulm

    Prof. Dr. med. R. Kreienberg

  6. Gynäkologie und Geburtshilfe, Evangelisches Krankenhaus, Kirchfeldstr. 40, 40217, Düsseldorf

    Prof. Dr. med. W. Meier

  7. Gynäkologie und Geburtshilfe, Malteser Krankenhaus Bonn/Rhein-Sieg, Von-Hompesch-Straße 1, 53123, Bonn

    Dr. med. M. Gropp

  8. Strahlenklinik-Interdisziplinäre Onkologie, Klinikum Offenbach, Starken burgring 66, 63069, Offenbach

    Prof. Dr. med. Dr. rer. nat. N. Zamboglou & Dr. med. N. Tselis

  9. Gänsbühlstraße 29, 73572, Heuchlingen

    Dr. med. R. Kurek

  10. Frauenklinik, Georg-August-Universität, Robert-Koch-Straße 40, 37075, Göttingen

    Prof. Dr. med. G. Emons

  11. Klinik für Gynäkologie, Gyn. Endokrinologie u. Onkologie, Universitätsklinikum Gießen u. Marburg, Baldingerstraße 1, 35043, Marburg

    Dr. rer. nat. S. Reinartz

  12. Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Universitätsklinikum Gießen und Marburg GmbH, Baldingerstraße 1, 35043, Marburg

    Prof. Dr. med. U. Wagner

  13. Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen

    PD Dr. med. P. Wimberger & Prof. Dr. med. R. Kimmig

  14. Klinikum Bremen-Mitte gGmbH, Klinik für Gynäkologie und Geburtshilfe, St.-Jürgen-Straße 1, 28177, Bremen

    Prof. Dr. med. W. Schröder

Authors
  1. Prof. Dr. med. B. Schmalfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. T. W. Park-Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. M. Pölcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. med. A. du Bois
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prof. Dr. med. R. Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Prof. Dr. med. W. Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dr. med. M. Gropp
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Prof. Dr. med. Dr. rer. nat. N. Zamboglou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dr. med. N. Tselis
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dr. med. R. Kurek
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Prof. Dr. med. G. Emons
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Dr. rer. nat. S. Reinartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Prof. Dr. med. U. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. PD Dr. med. P. Wimberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Prof. Dr. med. W. Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Prof. Dr. med. R. Kimmig
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schmalfeldt, B. et al. (2009). Epitheliales Ovarialkarzinom. In: Management des Ovarialkarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68857-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68857-0_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41987-7

  • Online ISBN: 978-3-540-68857-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation